Literature DB >> 1320628

Use of enzyme-linked immunosorbent assays with chimeric fusion proteins to titrate antibodies against Epstein-Barr virus nuclear antigen 1.

N Inoue1, J Kuranari, S Harada, H Nakajima, M Ohbayashi, Y Nakamura, N Miyasaka, K Ezawa, F Ban, K Yanagi.   

Abstract

Two new enzyme-linked immunosorbent assays (ELISAs) with chimeric fusion polypeptides for the detection of human antibodies specific to Epstein-Barr virus nuclear antigen 1 (EBNA-1) are described. One is an indirect ELISA with affinity-purified beta-galactosidase-EBNA-1 fusion protein as the antigen. The other is a "sandwich" assay based on the use of anti-beta-galactosidase antibody to capture beta-galactosidase-EBNA-1 fusion proteins in bacterial extracts. A good correlation was shown between antibody titers determined by the ELISA with the EBNA-1 fusion proteins and those determined by a conventional anticomplement immunofluorescence test which is being widely performed with Raji cells for the purpose of research and clinical diagnosis. The advantage of the ELISAs for seroepidemiologic studies on Epstein-Barr virus was demonstrated by sensitive detection of marginal immunoglobulin G antibody to the EBNA-1 domain in serum samples from patients with infectious mononucleosis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1320628      PMCID: PMC265307          DOI: 10.1128/jcm.30.6.1442-1448.1992

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  23 in total

1.  BamHI E region of the Epstein-Barr virus genome encodes three transformation-associated nuclear proteins.

Authors:  A Ricksten; B Kallin; H Alexander; J Dillner; R Fåhraeus; G Klein; R Lerner; L Rymo
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

2.  Synthesis of fusion proteins of Epstein-Barr virus nuclear antigens in E. coli and their antigenicity.

Authors:  N Inoue; S Harada; K Yanagi
Journal:  J Virol Methods       Date:  1991 Feb-Mar       Impact factor: 2.014

3.  Antibody response against the Epstein-Barr virus-coded nuclear antigen2 (EBNA2) in different groups of individuals.

Authors:  J M Seigneurin; M F Lavoue; O Genoulaz; G W Bornkamm; G M Lenoir
Journal:  Int J Cancer       Date:  1987-09-15       Impact factor: 7.396

4.  Kinetics of the antibody response to BamHI-K nuclear antigen in uncomplicated infectious mononucleosis.

Authors:  J C Niederman; G Miller
Journal:  J Infect Dis       Date:  1986-08       Impact factor: 5.226

5.  Epstein-Barr virus-related antibody patterns in ataxia-telangiectasia.

Authors:  A I Berkel; W Henle; G Henle; G Klein; F Ersoy; O Sanal
Journal:  Clin Exp Immunol       Date:  1979-02       Impact factor: 4.330

6.  Rheumatoid arthritis synovial membrane contains a 62,000-molecular-weight protein that shares an antigenic epitope with the Epstein-Barr virus-encoded associated nuclear antigen.

Authors:  R Fox; R Sportsman; G Rhodes; J Luka; G Pearson; J Vaughan
Journal:  J Clin Invest       Date:  1986-05       Impact factor: 14.808

7.  Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines.

Authors:  B M Reedman; G Klein
Journal:  Int J Cancer       Date:  1973-05       Impact factor: 7.396

Review 8.  The Epstein-Barr virus proteins.

Authors:  J Dillner; B Kallin
Journal:  Adv Cancer Res       Date:  1988       Impact factor: 6.242

9.  Evaluation of enzyme-linked immunosorbent assays with two synthetic peptides of Epstein-Barr virus for diagnosis of infectious mononucleosis.

Authors:  A Linde; B Kallin; J Dillner; J Andersson; L Jägdahl; A Lindvall; B Wahren
Journal:  J Infect Dis       Date:  1990-05       Impact factor: 5.226

10.  Epstein-Barr serology in immunodeficiencies: an attempt to correlate with immune abnormalities in Wiskott-Aldrich and Chediak-Higashi syndromes and ataxia telangiectasia.

Authors:  E Vilmer; G M Lenoir; J L Virelizier; C Griscelli
Journal:  Clin Exp Immunol       Date:  1984-02       Impact factor: 4.330

View more
  3 in total

1.  Elevated immunoglobulin G antibodies to the proline-rich amino-terminal region of Epstein-Barr virus nuclear antigen-2 in sera from patients with systemic connective tissue diseases and from a subgroup of Sjögren's syndrome patients with pulmonary involvements.

Authors:  M Yamazaki; R Kitamura; S Kusano; H Eda; S Sato; M Okawa-Takatsuji; S Aotsuka; K Yanagi
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

2.  Neutralization of measles virus infectivity and antibody-dependent cell-mediated cytotoxicity activity against an Epstein-Barr virus-infected cell line by intravenous immunoglobulin G [corrected].

Authors:  MariCarmen Colomar; Irene Puga; Maite López; Marta Massot; Juan I Jorquera; Manuel Reina; Senen Vilaró; Enric Espel
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

3.  Development of a recombinant enzyme-linked immunosorbent assay for detection of antibodies against Epstein-Barr virus nuclear antigens 2A and 2B.

Authors:  R Geertsen; A Espander-Jansson; M Dobec; P Price; W Wunderli; L Rymo
Journal:  J Clin Microbiol       Date:  1994-01       Impact factor: 5.948

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.